. 2021 Oct 20;3(4):100219. doi: 10.1016/j.ocarto.2021.100219

Table 2.

Identification in SF of 23 phospholipids significantly modulated between sample groups, using a targeted phospholipidomic analysis.

N	Phospholipids	m/z	MS mode	Non-OA controls (n = 4)	eOA (n = 7)	lOA (n = 8)	p-value
1	D-α-PC dipalmitoyl	734.60	POS	3793.00 ± 2196.00	4420.00 ± 1451.00	2033.00 ± 743.80^b	0.0162
2	PC 28:1	676.50	POS	378.70 ± 140.40	829.40 ± 389.50	322.10 ± 126.70^b	0.0053
3	PC 30:0	706.50	POS	807.00 ± 538.20	1034.00 ± 385.50	454.40 ± 147.40^b	0.0178
4	PC 32:1	732.60	POS	3524.00 ± 2149.00	4342.00 ± 1465.00	2057.00 ± 741.40^b	0.0231
5	PC 32:2	730.50	POS	1537.00 ± 1336.00	2490.00 ± 683.00^a	1098.00 ± 333.00^b	0.0007
6	PC 34:1	760.60	POS	215.20 ± 51.09	667.30 ± 285.40^a	311.80 ± 80.76^b	0.0004
7	PC 34:2	758.60	POS	12985.00 ± 5144.00	16386.00 ± 3784.00	9784.00 ± 3116.00^b	0.0152
8	PC 36:0	790.60	POS	9586.00 ± 4083.00	18282.00 ± 5341.00^a	12515.00 ± 3860.00	0.0173
9	PCaa 24:0	622.44	POS	9675.00 ± 3690.00	16992.00 ± 4246.00^a	11444.00 ± 3658.00^b	0.0211
10	PA 30:0	619.40	NEG	290.90 ± 40.75	213.50 ± 26.32^a	228.40 ± 32.35^a	0.0070
11	PE 30:0	622.50	NEG	111.10 ± 4.02	144.20 ± 15.05^a	139.30 ± 26.06^a	0.0259
12	PE 36:1	744.50	NEG	905.04 ± 533.40	1672.00 ± 328.70^a	1634.00 ± 311.60^a	0.0059
13	PE 36:2	742.50	NEG	325.50 ± 65.38	162.60 ± 30.85^a	179.10 ± 11.08^a	<0.0001
14	PG 34:2	745.50	NEG	218.10 ± 86.04	74.76 ± 16.90^a	87.17 ± 24.50^a	<0.0001
15	PS 32:1	732.50	NEG	98.56 ± 6.82	197.00 ± 59.97^a	163.00 ± 37.54^a	0.0059
16	PS 32:0	734.50	NEG	497.20 ± 111.00	1070.00 ± 174.00^a	1079.00 ± 156.00^a	<0.0001
17	PI 26:0	725.50	NEG	344.20 ± 26.65	455.60 ± 13.88^a	455.90 ± 12.41^a	<0.0001
18	PI 30:0	781.60	NEG	797.00 ± 39.04	649.40 ± 48.82^a	686.30 ± 63.13^a	0.0038
19	PI 32:1	807.60	NEG	596.10 ± 45.55	900.50 ± 102.60^a	923.60 ± 178.30^a	0.0005
20	PI 34:1	835.60	NEG	1366.00 ± 73.98	1711.00 ± 115.50^a	1725.00 ± 96.94^a	<0.0001
21	PI 36:2	861.70	NEG	362.60 ± 63.57	648.20 ± 74.20^a	708.00 ± 52.91^a	<0.0001
22	PI 36:1	863.70	NEG	452.70 ± 148.80	669.10 ± 79.20^a	675.20 ± 95.91^a	0.0032
23	PI 36:0	865.70	NEG	186.50 ± 37.84	319.80 ± 56.48^a	326.30 ± 63.73^a	0.0005

Data are presented as mean ± SD, unless indicated. ANOVA F-test (FDR corrected <0.05) was used.

eOA: early-stage osteoarthrtitis; lOA: late-stage osteoarthritis; POS: positive ion mode; NEG: negative ion mode; PC: phosphatidylcholine; PA: phosphatidic acid; PE: phosphatidylethanolamine; PG: phosphatidylglycerol; PS: phosphatidylserine; PI: phosphatidylinoisitol.

Significant difference from control SF.

Significant difference from eOA SF.